Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 4 Thyroid Carcinoma, Anaplastic 3 Neoplasms 3 Glioma 2 Colorectal Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Thyroid Neoplasms 1 Spinocerebellar Degenerations 1 Solid Tumor 1 Skin Neoplasms 1 Sexual Dysfunction, Physiological 1 Refractory Differentiated Thyroid Gland Carcinoma 1 Recurrence 1 Rare Malignant Neoplasm 1 Neoplasm Metastasis 1 Multiple Myeloma 1 Lymphoma, Non-Hodgkin 1 Lung Neoplasms 1 Locally Advanced Thyroid Gland Carcinoma 1 Hematologic Neoplasms 1 Eunuchism 1 Erectile Dysfunction 1 Craniopharyngioma 1 Brain Neoplasms 1 Ameloblastoma 1 Advanced Thyroid Cancer Patients Who Received Target Therapy 1

Interventions

trifluridine tipiracil drug combination 1 trametinib 1 tovorafenib 1 tocilizumab 1 dabrafenib 1 binimetinib 1 anlotinib 1 Surveys and Questionnaires 1 Qsymia 1 Phentermine 1 Oxaliplatin 1 Nivolumab 1 Leucovorin 1 Fluorouracil 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Craniopharyngioma × dabrafenib × Clear all

NCT05525273 2024-02-14

Swecranio

Skane University Hospital

Phase 2 Recruiting

Craniopharyngioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡